Ahmed 青光眼引流阀植入治疗 Fuchs 葡萄膜炎相关性青光眼的疗效观察。

Outcomes of Ahmed Glaucoma Valve Implantation for Glaucoma Secondary to Fuchs Uveitis Syndrome.

机构信息

a Centre for Ophthalmology , University Hospital Tuebingen , Tuebingen , Germany.

出版信息

Ocul Immunol Inflamm. 2017 Dec;25(6):760-766. doi: 10.3109/09273948.2016.1168454. Epub 2016 May 18.

DOI:10.3109/09273948.2016.1168454

PMID:27191797

Abstract

PURPOSE

To present the outcomes of Ahmed glaucoma valve implantation (AGV) in glaucoma secondary to Fuchs uveitis syndrome (FUS).

METHODS

In this retrospective chart review, two definitions of success were used: 6 mmHg ≤intraocular pressure (IOP) ≤21 mmHg (success 1), and 6 mmHg ≤ IOP ≤21 mmHg and at least 25% reduction from baseline (success 2). Depending on the need of postoperative antiglaucoma medication, success was defined as either complete or qualified.

RESULTS

In total, 17 eyes of 17 patients were included. Complete success rates (both definitions) were 23.5% (n = 17) after 1 year and 23% (n = 13) after 3 years. Qualified success rates (both definitions) were 58.3% (n = 17) after 1 and 38.4% (n = 13) after 3 years. Encapsulated bleb formation was the most common complication (47% of eyes).

CONCLUSIONS

AGV was moderately successful in the management of glaucoma secondary to FUS. Success rates are improved by medications, needling, and cycloablative procedures.

摘要

目的

介绍 Ahmed 青光眼引流阀植入（AGV）治疗 Fuchs 葡萄膜炎综合征（FUS）继发青光眼的结果。

方法

在这项回顾性图表研究中，使用了两种成功定义：眼压（IOP）为 6mmHg≤6mmHg≤21mmHg（成功 1），IOP 为 6mmHg≤6mmHg≤21mmHg，且与基线相比降低至少 25%（成功 2）。根据术后抗青光眼药物的需要，成功定义为完全或合格。

结果

共纳入 17 例患者的 17 只眼。术后 1 年完全成功率（两种定义）分别为 23.5%（n=17）和 23%（n=13），术后 3 年分别为 23.5%（n=17）和 23%（n=13）。完全成功率（两种定义）分别为 58.3%（n=17）和 38.4%（n=13）。包膜性滤过泡形成是最常见的并发症（47%的眼）。